The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Vizamyl flutemetamol (18F) | GE Healthcare AS | Radionuclide Imaging; Alzheimer Disease | 🇪🇺 EU 2014-08-22 | Order → |
| Translarna ataluren ConditionalAdditional monitoring | PTC Therapeutics International Limited | Muscular Dystrophy, Duchenne | 🇪🇺 EU 2014-07-31 | Order → |
| Gazyvaro obinutuzumab | Roche Registration GmbH | Leukemia, Lymphocytic, Chronic, B-Cell | 🇪🇺 EU 2014-07-22 | Order → |
| Nuwiq simoctocog alfa | Octapharma AB | Hemophilia A | 🇪🇺 EU 2014-07-22 | Order → |
| Envarsus tacrolimus | Chiesi Farmaceutici S.p.A. | Graft Rejection | 🇪🇺 EU 2014-07-18 | Order → |
| Plegridy peginterferon beta-1a | Biogen Netherlands B.V. | Multiple Sclerosis | 🇪🇺 EU 2014-07-18 | Order → |
| Simbrinza brinzolamide;brimonidine tartrate | Novartis Europharm Limited | Ocular Hypertension; Glaucoma, Open-Angle | 🇪🇺 EU 2014-07-18 | Order → |
| Mekinist trametinib | Novartis Europharm Limited | Melanoma | 🇪🇺 EU 2014-06-30 | Order → |
| Ebilfumin oseltamivir Generic | Actavis Group PTC ehf | Influenza, Human | 🇪🇺 EU 2014-05-22 | Order → |
| Entyvio vedolizumab | Takeda Pharma A/S | Colitis, Ulcerative; Crohn Disease | 🇪🇺 EU 2014-05-22 | Order → |
| Jardiance empagliflozin | Boehringer Ingelheim International GmbH | Diabetes Mellitus, Type 2; Heart Failure; Renal Insufficiency, Chronic | 🇪🇺 EU 2014-05-22 | Order → |
| Sylvant siltuximab Accelerated assessmentAdditional monitoring | Recordati Netherlands B.V. | Giant Lymph Node Hyperplasia | 🇪🇺 EU 2014-05-22 | Order → |
| Olysio simeprevir Additional monitoring | Janssen-Cilag International NV | Hepatitis C, Chronic | 🇪🇺 EU 2014-05-14 | Order → |
| Anoro Ellipta (previously Anoro) umeclidinium bromide;vilanterol | GlaxoSmithKline Trading Services Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2014-05-08 | Order → |
| Laventair Ellipta (previously Laventair) umeclidinium bromide;vilanterol | GlaxoSmithKline Trading Services Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2014-05-08 | Order → |
| Revinty Ellipta fluticasone furoate;vilanterol | GlaxoSmithKline Trading Services Limited | Asthma | 🇪🇺 EU 2014-05-02 | Order → |
| BiResp Spiromax budesonide;formoterol | Teva Pharma B.V. | Pulmonary Disease, Chronic Obstructive; Asthma | 🇪🇺 EU 2014-04-28 | Order → |
| DuoResp Spiromax budesonide;formoterol | Teva Pharma B.V. | Pulmonary Disease, Chronic Obstructive; Asthma | 🇪🇺 EU 2014-04-28 | Order → |
| Incruse Ellipta (previously Incruse) umeclidinium bromide | GlaxoSmithKline Trading Services Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2014-04-28 | Order → |
| Deltyba delamanid | Otsuka Novel Products GmbH | Tuberculosis, Multidrug-Resistant | 🇪🇺 EU 2014-04-27 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.